Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Onco Innovations Ltd (QB) ONNVF

Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments. The company’s lead product candidate is ONC010, a novel inhibitor of the DNA repair enzyme a Polynucleotide Kinase 3'-Phosphatase (PNKP) in a nanoparticle formulation based on the drug delivery technology. Onco-Innovations Limited is headquartered in Calgary, Canada.

Current News (OTCQB:ONNVF)

Onco-Innovations Announces Initiation of Research Collaboration within PROmAI

ACCESS Newswire 1 day ago

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology

ACCESS Newswire 5 days ago

Onco-Innovations Announces Inka Health Collaborative Research to Advance Oncology Evidence Generation

ACCESS Newswire 8 days ago

Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies

ACCESS Newswire 12 days ago

Onco-Innovations Announces Successful Scale-Up of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for its PNKP Inhibitor Technology Program

ACCESS Newswire April 28, 2026

Onco-Innovations Advances Polymer Testing as It Moves Its PNKP Inhibitor Technology Toward IND-Enabling Studies

ACCESS Newswire April 23, 2026

Onco-Innovations Announces Completion of Analytical Method Development for Monomer Intermediate 1 Supporting ONC010 Program

ACCESS Newswire April 21, 2026

Onco-Innovations Strengthens Executive Leadership with Appointment of Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development

ACCESS Newswire April 17, 2026

Onco-Innovations Executes Engagement Agreement with RDI Partners and Establishes Onco-Innovations AU Pty. Ltd. to Advance Australian Phase I Strategy

ACCESS Newswire April 7, 2026

Opinion & Analysis (OTCQB:ONNVF)

No current opinion is available.

Bullboard Posts (OTCQB:ONNVF)

fund manager Martin Mathieu comment

THE UGLY Due to a regulatory request by the CSE, Onco-Innovations (CSE: ONCO) published an update on the use of proceeds from...
Possibleidiot01 - April 2, 2025

RE:Bulishh Oncooo

I think they are just getting started. I won't suprise if a Big Pharma comes along and aquires them 
JasonAchane - February 10, 2025

very bullish on this! serious tech for a serious cause.

Onco-Innovations just announced that their technology has demonstrated a statistically significant increase in the sensitivity of cancer...
JasonAchane - February 10, 2025

Bullish !

Has been great volume and price gains. A lot of knew technologies ready to explode ! This me the game changer that Dr.s  are looking...
becker123456789 - January 25, 2025

Podcasts